Clinical Trial Site

Bobigny 93000

2 studies enrolling now · 2 studies all time

What they study most

Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma, High Cardiovascular Risk, High Risk Cardiovascular Disease, Hypertension, Locally Advanced Breast Cancer, Metastatic Breast Cancer

Studies at this site

• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer — Recruiting now
• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease — Recruiting now